Vericel to Present at the Stephens Annual Investment Conference
07 Novembre 2023 - 2:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that Nick Colangelo, President and CEO and Joe Mara, CFO
will present at the Stephens Annual Investment Conference. The
fireside chat will begin at 10:00 a.m. ET (9:00 a.m. CT) on
Wednesday, November 15, 2023.
A webcast of the presentation will be available on the Investor
Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel Corporation
Vericel is a leader in advanced therapies for sports medicine
and severe burn care. The Company manufactures and markets two cell
therapy products and one specialty biologic product in the United
States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts)
is a permanent skin replacement for the treatment of patients with
deep dermal or full thickness burns greater than or equal to 30% of
total body surface area. Vericel also holds an exclusive license
for North American rights to NexoBrid® (anacaulase-bcdb), a
biological orphan product containing proteolytic enzymes, which is
indicated for the removal of eschar in adults with deep
partial-thickness and/or full-thickness burns. For more
information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound
Ltd. and is used under license to Vericel Corporation. © 2023
Vericel Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact:Julie Downsmedia@vcel.com
Grafico Azioni Vericel (NASDAQ:VCEL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Vericel (NASDAQ:VCEL)
Storico
Da Giu 2023 a Giu 2024